Hong Kong Genome Institute and Global Leaders Co-organise Landmark Healthcare Event "International Genomic Medicine Symposium"
Convening Experts to Promote Hong Kong and Advance Medical Innovation
International Genomic Medicine Symposium
17 November 2025, Hong Kong
Charles K. Kao Auditorium, Hong Kong Science Park
Time
Programme
Speaker
09:00
Keynote
Prof Lo Chung-mau, BBS, JP
Secretary for Health
Hong Kong SAR Government,
Hong Kong, China
09:15
Opening Ceremony
Panel 1
Session Chairperson:
Dr Ronald Lam, JP
Director of Health
Hong Kong SAR Government,
Hong Kong, China
09:30
Developing Rare Disease Models in China: Service, Teaching and Research
Prof Zhang Shuyang
President
Peking Union Medical College Hospital, China 10:00
Unraveling Molecular Pathogeneses to Enhance Patient Care and Family Well-being
Prof Kym Boycott
Co-Chair
Lancet Commission on Rare Diseases
Professor of Pediatrics
University of Ottawa, Canada
10:30
Panel Discussion
Panel 2
Session Chairperson:
Dr Libby Lee, JP
Under Secretary for Health
Hong Kong SAR Government,
Hong Kong, China
11:15
Insights into Rare Diseases:
Focus on Inborn Errors of Metabolism
Prof Roberto Giugliani
Co-Chair
Lancet Commission on Rare Diseases
Professor of Genetics
Federal University of Rio Grande do Sul, Brazil
11:45
Hong Kong Genome Project Case Sharing (1) – Unlocking the Genomics of Cardiomyopathy: A New Era in Heart Health
Dr Derek Lee
Hong Kong College of Physicians –
Hong Kong Genome Institute Scholar
Hong Kong, China
12:00
Hong Kong Genome Project Case Sharing (2) – Precision Medicine in Nephrology
Dr Becky Ma
Hong Kong Academy of Medicine –
Hong Kong Genome Institute Scholar
Hong Kong, China
12:15
Panel Discussion
12:30
Lunch
Panel 3
Session Chairperson:
Prof Philip Chiu
Dean of Medicine
The Chinese University of Hong Kong,
Hong Kong, China
14:00
Revolutionising Plasma DNA Analysis in Transforming Non-invasive Testing and Cancer Detection
Prof Dennis Lo, SBS, JP
Vice-Chancellor and President
The Chinese University of Hong Kong
Board Member
Hong Kong Genome Institute
Hong Kong, China
14:30
Publishing at The Lancet
Dr Chloe Wilson
Senior Medical Editor
The Lancet
15:00
Panel Discussion
Panel 4
Session Chairperson:
Prof Lau Chak-sing, BBS, JP
Vice-President & Pro-Vice-Chancellor (Health)
Dean of Medicine
The University of Hong Kong
Board Member
Hong Kong Genome Institute
Hong Kong, China
15:35
AI in Action:
The Journey from Clinical Record to Personalised Treatment
Prof Gareth Baynam
Medical Director
Rare Care Centre
Perth Children's Hospital, Australia
16:05
Harnessing the Power of Electronic Healthcare Records in Scientific Research and Innovation in Genomic Medicine
Prof Yong Chen
Professor of Biostatistics
University of Pennsylvania, USA
16:35
Panel Discussion Panel 5
Session Chairperson:
To be confirmed
16:50
The Health Rights of Children and Genomic Newborn Screening
Prof Bartha Knoppers
Director
Centre of Genomics and Policy
McGill University, Canada
17:20
Hong Kong Genome Project:
Advancing the Genomics Frontier
Dr Brian Chung
Chief Medical and Scientific Officer
Hong Kong Genome Institute,
Hong Kong, China
17:40
Genomics as a Catalyst for
Drug Development in the Greater Bay Area
Prof Aya El Helali
Clinical Assistant Professor
Department of Clinical Oncology,
School of Clinical Medicine,
The Li Ka Shing Faculty of Medicine of the University of Hong Kong,
Hong Kong, China
18:00
Panel Discussion
18:15
End of Symposium
(Last updated on 25 June 2025)
Enquiry
Hong Kong Genome Institute
Website: www.hkgp.org
Email:
Rare Disease International
Website: www.rarediseasesinternational.org
Email:
Hong Kong Genome InstituteWebsite: www.hkgp.orgEmail: [email protected] Rare Disease InternationalWebsite: www.rarediseasesinternational.orgEmail: [email protected]
HONG KONG SAR - Media OutReach Newswire - 25 June 2025 - Genomic medicine is one of the most promising fields in today's healthcare landscape, enabling precise diagnoses, personalised treatment plans, and breakthroughs in drug development that bring new hope to patients around the world. Thewill join forces with world-renowned authorities to host the(Symposium) on 17 November 2025 (Monday). This landmark event will highlight Hong Kong's unique strengths in fostering exchange and cooperation with experts worldwide in medical research and innovation, and accelerate the application of genomic medicine to pave the way for a healthier future for all.The Symposium marks HKGI's first collaboration withand, which is jointly led by RDI and, the world's most influential medical journal. The event will welcome local and international genomics leaders from over 20 countries and regions, including clinicians, scientists, and researchers from Mainland China, Europe, North and South America, and Australia.Distinguished speakers at the Symposium will focus on key global topics such as clinical genetics, rare diseases, genomic medicine, AI, data sharing, as well as ethical and legal matters involved, facilitating in-depth discussions on the latest groundbreaking research and clinical insights. Specifically, thematic sessions will be dedicated to experience sharing by experts from Mainland China and Hong Kong. By showcasing case studies from the Hong Kong Genome Project, these exchanges will help demonstrate practical applications of personalised medicine in managing common disorders such as cardiomyopathy and kidney disease. Developments in rare diseases in Mainland China and drug development opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area will also be covered, opening doors of opportunity for regional collaboration and innovation.said, "With the strong support from the Health Bureau of the Hong Kong SAR Government, HKGI has been working closely with the Department of Health, Hospital Authority, medical schools of local universities and various stakeholders to accelerate the development of genomic medicine in Hong Kong. In just a few years, the Institute has achieved significant milestones in medical research, clinical applications, and international collaborations. We have successfully recruited over 47,000 participants for the Hong Kong Genome Project, continuously expanding our genome database featuring the Southern Chinese population. We have also accumulated clinical application cases and established synergistic collaborative research platforms. These achievements highlight Hong Kong's strong capabilities and advantages in genomic medicine, laying a solid foundation for further collaboration with internationally recognised authorities."continued, "We are greatly honoured to partner with RDI and LCRD to organise this prestigious global event. Genomic medicine is the future of medicine with wide-ranging applications, spanning from common to rare diseases, from clinical diagnosis and personalised treatment to disease prevention and health management. This Symposium will undoubtedly serve as a critical platform for healthcare experts, academics, and researchers from around the world to exchange knowledge, fostering collaboration, and driving medical innovation, ultimately bringing immense benefits to patients in Hong Kong, Asia and beyond."The one-day Symposium is expected to attract nearly 300 industry professionals. Following the Symposium, the LCRD will hold its annual meeting in Hong Kong on 18-19 November to further discuss insights and deepen cross-regional collaboration. This will be the first time for the LCRD to host its annual meeting in Asia, highlighting Hong Kong's distinctive position in leading international medical innovation.For information about the Symposium programme and speakers, please refer to the appendix. For enquiries about the Symposium, please contact HKGI (
[email protected] ) or RDI-LCRD (
[email protected] ).Hashtag: #HongKongGenomeInstitute
The issuer is solely responsible for the content of this announcement.
About Hong Kong Genome Institute
The Hong Kong Genome Institute (HKGI), established and wholly owned by the Hong Kong SAR Government, commenced full operations in 2021. With the vision "to avail genomic medicine to all for better health and well-being" and supported by the Health Bureau, HKGI works in close collaboration with the Department of Health, Hospital Authority, medical schools of local universities and other stakeholders to accelerate the development of genomic medicine in Hong Kong along four strategic foci: integrate genomics into medicine, advance research, nurture talents and enhance public genomic literacy.
As the first step towards achieving its vision, HKGI launched the Hong Kong Genome Project (HKGP) in 2021 focusing on diseases and research cohorts that would benefit from whole genome sequencing. They include undiagnosed diseases, hereditary cancers and cases related to genomics and precision health. Being the city's first large-scale genome sequencing project, HKGP serves as a catalyst to benefit patients and their families with more precise diagnosis and personalised treatment. It also aims to establish genome database of the local population, testing infrastructure and talent pool to address the healthcare needs of Hong Kong in the long run.
For more information, please visit https://hkgp.org/en.
About Rare Diseases International
Rare Diseases International (RDI) is the global alliance of people living with a rare disease of all nationalities across all rare diseases. RDI's mission is to be a strong common voice on behalf of rare disease patients around the world, to advocate for rare diseases as an international public health priority and to represent its members and enhance their capacities. RDI has more than 120 member organizations from 50 countries, which in turn represent rare disease patient groups in more than 150 countries worldwide.
For more information, please visit https://www.rarediseasesinternational.org.
About Lancet Commission on Rare Diseases
The RDI-Lancet Commission on Rare Diseases (RDI-LCRD) is a new initiative dedicated to improving the lives of Persons Living with a Rare Disease (PLWRD) globally by generating evidence-informed recommendations that can be implemented in all countries. The RDI-LCRD, chaired by Dr Roberto Giugliani (Brazil) and Dr Kym Boycott (Canada) brings together 27 Commissioners from 6 continents with a broad range of expertise, perspectives and experience. The overarching goal of the RDI-LCRD is to use robust data to ignite global action that will amplify the voices of PLWRD and ensure that they are seen, heard, and cared for, no matter where they live.
For more information, please visit http://www.rarediseasescommission.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
3 hours ago
- Malay Mail
Imported fruits getting too pricey? Here are local alternatives that outshine them in nutrition
KUALA LUMPUR, June 30 — With the revised and expanded Sales and Service Tax (SST) on imported goods set to take effect next month, Malaysians are bracing for a significant increase in the prices of imported fruits. Earlier this month, the government announced a targeted SST review that will take effect on July 1, 2025, which will include imported fruits, except apples and oranges. With the new taxes in place, consumers may find imported fruits like berries, grapes, and cherries becoming more expensive. However, Malaysia has a diverse range of local fruits that not only rival but often surpass their imported counterparts in nutritional value. As a result, budget-conscious Malaysians may turn to these local alternatives, which offer both flavour and nutrition. Local fruits that beat imports While enjoying a diverse array of fruits from around the world is certainly a delightful experience, it's equally important to recognise and appreciate the worthy options found locally. Here's a list of local fruits that can be a great alternative to their imported counterparts in terms of nutrition and minerals: Apples vs guava While apples are often branded as a healthy fruit for their fibre content and low-calorie count, guava steps up with even higher fibre and an impressive vitamin C boost, offering antioxidant benefits that surpass those of apples. For comparison, 100g of guava contains 5.4g of dietary fibre compared to an apple, which only has 2.4g. The same amount of guava also has an impressive 228mg of vitamin C, while apple only has 4.6mg. Blueberries vs mangosteen Known for their antioxidant properties, blueberries are often sought after for their antioxidant content. Mangosteen, with its potent xanthones, offers similar antioxidant benefits plus additional anti-inflammatory effects. Research suggests that xanthones offer a range of potential health benefits, including anti-cancer, and antimicrobial properties. Grapes vs langsat Grapes are a popular source of antioxidants and Vitamin K, responsible for bone health and the healing of injuries. Langsat, on the other hand, offers similar benefits, plus it contains B vitamins that are crucial for energy production. Strawberries vs rambutan Both these fruits are rich in vitamin C and antioxidants. Rambutan also offers vitamin A and other minerals such as manganese, copper, potassium, calcium, and magnesium. Orange vs papaya Papaya is a great substitute for oranges when it comes to vitamin C content. For comparison, 100g of papaya provides over 60mg of vitamin C, which is about 20 per cent higher than an equivalent serving of orange. Malaysia boasts a variety of local fruits that offer superior nutrition and minerals compared to their imported counterparts. — Picture by Firdaus Latif Do imported fruits have higher nutritional value? Despite a common perception that imported fruits are more premium, largely due to their exotic appeal and higher price tags, local fruits may often be a fresher alternative to their imported counterparts. The perceived superiority of imported fruits is often linked to branding and prestige, overlooking key aspects such as freshness and nutritional value in homegrown fruits. Additionally, imported fruits, by nature of their long journey from their country of origin, must go through rigorous logistical processes to reach Malaysian shelves. These processes often include treatments like waxing and deep freezing to stretch shelf life. For instance, apples and citrus fruits are sometimes coated with a thin layer of wax to preserve moisture and maintain their appearance during the multi-week shipping transit, haulage, and sorting before they hit the shelves. Such processes and the lengthy journey can often impact their taste, texture or even nutritional value. In contrast, Malaysian fruits, being locally grown and harvested, offer greater freshness. Often picked at peak ripeness, the short supply chain from local farms to markets means that they are less likely to undergo any preservation processes, making them an even healthier option.
Malay Mail
a day ago
- Malay Mail
SST on outpatient care for foreign workers could backfire, say private GPs pushing for urgent exemption
KUCHING, June 29 — The Federation of Private Medical Practitioners' Associations, Malaysia (FPMPAM) has proposed for the government to fully exempt primary care services for foreign workers from the Sales and Services Tax (SST). FPMPAM president Dr Shanmuganathan Ganeson said that as an alternative, the government could implement a temporary moratorium on the tax to allow time to explore a fair and sustainable healthcare financing mechanism. 'We have formally submitted an appeal to the Ministry of Finance (MoF), urging an urgent exemption from the upcoming six per cent SST on primary healthcare services provided to foreign workers, scheduled to take effect on July 1,' he said in a statement. Dr Shanmuganathan said although the Foreign Workers Medical Examination Monitoring Agency (Fomena) screenings remained exempt, many foreign workers would still require outpatient care for common illnesses, injuries, and chronic conditions — essential services typically paid for out-of-pocket by the workers themselves, or arranged through employer or Third-Party Administrator (TPA) programmes. Under the new SST rules, such services would be taxed once a clinic's annual revenue exceeds RM1.5 million. Dr Shanmuganathan said: 'The foreign workers are already vulnerable and underserved, and the SST to basic medical treatment risks deterring them from seeking timely care, delaying diagnosis, and ultimately compromising public health. 'We are also concerned about the eight per cent SST on commercial property rentals, which would further escalate operating costs for clinics renting shoplots, medical suites, or office units. 'These taxes compound the strain on solo and small-group practices that have seen no fee adjustments for decades.' Dr Shanmuganathan also highlighted that the Federation of Malaysian Manufacturing (FMM) recently called for a broader reassessment of the SST expansion, citing its potential to harm the business environment and consumers. 'FPMPAM echoes this concern, urging the MoF to prioritise public health and service sustainability. 'FPMPAM also notes a policy anomaly where beauticians and cosmeticians, which are not related to essential health, now have no tax, whilst tax is imposed for essential health and medical services.' Nonetheless, Dr Shanmuganathan said the federation stood ready to work with the MoF to ensure that tax policies would not inadvertently undermine access to essential healthcare or threaten the survival of community clinics. — The Borneo Post
Malay Mail
a day ago
- Malay Mail
Health minister: Singapore to raise first-time blood donor age limit to 65 from 2026
SINGAPORE, June 29 — From January 1, 2026, the age limit for first-time blood donors in Singapore will be raised from 60 to 65, Health Minister Ong Ye Kung announced yesterday. According to Channel News Asia (CNA), Ong said the move aims to expand the donor pool amid rising demand and an ageing population. He also said the decision reflects longer life expectancy and data showing fewer adverse reactions among older donors. 'There is no reason to believe that once you cross 60 years old, suddenly the adverse reaction prevalence rate is going to shoot up,' he reportedly said at a World Blood Donor Day event yesterday. Singapore's new limit brings it in line with countries such as the United Kingdom and South Korea. Currently, only repeat donors can give blood beyond age 60, if they meet health criteria. The country's blood supply remains under pressure, with new donor numbers falling and demand increasing — over 35,000 patients required transfusions in 2023. Seasonal dips and past critical shortages, especially in Group O blood, have also posed challenges.
